Loading…
Loading…
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECHTM ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.
Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.
KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.
Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement (“ MTA ”) with Pegbio Co., Ltd (“ PegBio ”) to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company . The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1 molecule which will then be processed with Lexaria's patented DehydraTECH technology and evaluated for pharmacokinetic performance in animal studies.
Kelowna, British Columbia – TheNewswire - July 30, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the “ Reverse Split ”). The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's (“ Nasdaq ”) minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Price Rule ”). The Reverse Split is also being performed in an effort to stabilize uncertain stock conditions in the face of a number of critical business drivers which we believe to be in the best immediate and long-term interests of our shareholders.
KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the "Reverse Split"). The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's ("Nasdaq") minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) (the "Minimum Price Rule").
KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention ("BIO") in San Diego, CA. "Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies," said Richard Christopher, CEO of Lexaria Bioscience Corp. "We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent of entering into partnership arrangements.
Kelowna, British Columbia – July 6, 2026 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention (“BIO”) in San Diego, CA. “Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies,” said Richard Christopher, CEO of Lexaria Bioscience Corp. “We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent of entering into partnership arrangements. Not a week goes by without discussion with one or more potential partners.”